This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2006 Apr;3(4):170-1.

doi: 10.1038/ncponc0476.

EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer

Jonathan E Dowell¹, John D Minna

Affiliations

PMID: 16596125
DOI: 10.1038/ncponc0476

EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer

Jonathan E Dowell et al. Nat Clin Pract Oncol. 2006 Apr.

. 2006 Apr;3(4):170-1.

doi: 10.1038/ncponc0476.

Authors

Jonathan E Dowell¹, John D Minna

Affiliation

¹ University of Texas Southwestern Medical Center, Dallas, TX 75390-8593, USA.

PMID: 16596125
DOI: 10.1038/ncponc0476

No abstract available

PubMed Disclaimer

Similar articles

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
Heigener DF, Reck M. Heigener DF, et al. Adv Ther. 2011 Feb;28(2):126-33. doi: 10.1007/s12325-010-0096-4. Epub 2010 Dec 16. Adv Ther. 2011. PMID: 21181318 Review.
Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Reddy GK. Reddy GK. Clin Lung Cancer. 2005 Nov;7(3):163-5. doi: 10.1016/S1525-7304(11)70404-1. Clin Lung Cancer. 2005. PMID: 16354309 Review. No abstract available.
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
Pao W, Miller VA. Pao W, et al. J Clin Oncol. 2005 Apr 10;23(11):2556-68. doi: 10.1200/JCO.2005.07.799. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767641 Review.
Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
[No authors listed] [No authors listed] Technol Eval Cent Assess Program Exec Summ. 2011 Mar;25(6):1-5. Technol Eval Cent Assess Program Exec Summ. 2011. PMID: 21638942 No abstract available.
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
Uramoto H, Mitsudomi T. Uramoto H, et al. Br J Cancer. 2007 Mar 26;96(6):857-63. doi: 10.1038/sj.bjc.6603665. Epub 2007 Feb 27. Br J Cancer. 2007. PMID: 17325698 Free PMC article. Review.

See all similar articles

Cited by

The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer.
Fan Q, Wang Q, Cai R, Yuan H, Xu M. Fan Q, et al. Cell Mol Biol Lett. 2020 Jan 16;25:1. doi: 10.1186/s11658-019-0193-6. eCollection 2020. Cell Mol Biol Lett. 2020. PMID: 31988639 Free PMC article. Review.
Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance.
Hatanpaa KJ, Burma S, Zhao D, Habib AA. Hatanpaa KJ, et al. Neoplasia. 2010 Sep;12(9):675-84. doi: 10.1593/neo.10688. Neoplasia. 2010. PMID: 20824044 Free PMC article. Review.
Genetic mutation of p53 and suppression of the miR-17∼92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D Signaling.
Borkowski R, Du L, Zhao Z, McMillan E, Kosti A, Yang CR, Suraokar M, Wistuba II, Gazdar AF, Minna JD, White MA, Pertsemlidis A. Borkowski R, et al. Cancer Res. 2015 Feb 15;75(4):666-75. doi: 10.1158/0008-5472.CAN-14-1329. Epub 2014 Dec 17. Cancer Res. 2015. PMID: 25519225 Free PMC article.
Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma.
Levy M, Lyon L, Barbero E, Wong J, Suga M, Sam D, Pan M. Levy M, et al. Med Sci (Basel). 2017 Dec 11;5(4):34. doi: 10.3390/medsci5040034. Med Sci (Basel). 2017. PMID: 29232915 Free PMC article.
Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer.
Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown P. Speers C, et al. Clin Cancer Res. 2009 Oct 15;15(20):6327-40. doi: 10.1158/1078-0432.CCR-09-1107. Epub 2009 Oct 6. Clin Cancer Res. 2009. PMID: 19808870 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Grants and funding

P50CA70907/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal